Metabolism of 4-(3-cyclohexylpropionyl)-1-(2-ethoxyphenyl) piperazine (D-16120) by rat liver microsomes.
The metabolic fate of central analgesic 4-(3-cyclohexylpropionyl)-1-(2-ethoxyphenyl) piperazine (D-16120), was studied in vitro with phenobarbital 3-methylcholanthrene and clofibrate induced rat liver microsomal fractions. The presence of four metabolites was directly or indirectly established. Biotransformation products were isolated by TLC and HPLC techniques and, when possible, the structures were confirmed through comparison with synthetic samples. The metabolic pathways involved are oxidative dealkylation, aromatic and alicyclic hydroxylation.
Caputo
O
O
Dipartimento di Scienza e Tecnologia del Farmaco, Università di Torino, Italy.
Rocco
F
F
Grosa
G
G
D000700:Analgesics / Q000138:chemical synthesis / Q000378:metabolism* / Q000493:pharmacokinetics; D000818:Animals; D001711:Biotransformation; D002851:Chromatography, High Pressure Liquid; D002855:Chromatography, Thin Layer; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D013058:Mass Spectrometry; D008862:Microsomes, Liver / Q000378:metabolism*; D009249:NADP / Q000378:metabolism; D010879:Piperazines / Q000138:chemical synthesis / Q000378:metabolism* / Q000493:pharmacokinetics; D051381:Rats; D017208:Rats, Wistar
D000700:Analgesics; D010879:Piperazines; D009249:NADP; C093408:4-(3-cyclohexylpropionyl)-1-(2-ethoxyphenyl)piperazine